A predictive transcriptomic signature of oropharyngeal cancer according to HPV16 status exclusively

• Published in: Oral oncology 2014-11, Vol.50 (11), p.1025-1034
• Main Authors: Mirghani, Haitham, Ugolin, Nicolas, Ory, Catherine, Lefèvre, Marine, Baulande, Sylvain, Hofman, Paul, St Guily, Jean Lacau, Chevillard, Sylvie, Lacave, Roger
• Format: Article
• Language: English
• Subjects: Aged; Alphapapillomavirus - genetics; Alphapapillomavirus - isolation & purification; Biological and medical sciences; DNA-microarray; Female; Gene expression profile; Hematology, Oncology and Palliative Medicine; Human papillomavirus 16; Humans; Male; Medical sciences; Middle Aged; Multiple tumors. Solid tumors. Tumors in childhood (general aspects); Oligonucleotide Array Sequence Analysis; Oropharyngeal Neoplasms - genetics; Oropharyngeal Neoplasms - virology; Oropharyngeal/oropharynx cancer; Otolaryngology; Otorhinolaryngology. Stomatology; p16; Transcriptome; Tumors; Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology
• ISSN: 1368-8375; 1879-0593
• DOI: 10.1016/j.oraloncology.2014.07.019

Summary Objective Human-papillomaviruses (HPV) type 16 is a causative agent in an increasing subset of oropharyngeal squamous cell carcinomas (OPSCCs). These tumors have distinct oncogenic mechanisms and a more favorable prognosis than tobacco-induced OPSCCs. Although these differences emphasize the need for a specific therapeutic approach, HPV status is still not used to guide treatment. A better characterization of the molecular profile related to HPV16-induced OPSCC might help to develop personalized treatments. Patients and methods Using a human whole-genome DNA-microarray, we have examined the gene expression profiles in 15 HPV-negative and 15 transcriptionally-active HPV-positive OPSCCs. The study was conducted in two steps. Firstly, a learning/training-set consisting of 8 HPV16-positive and 8 HPV16-negative OPSCCs was analyzed to identify a specific signature. Potentially confounding factors (stage, sex and tobacco) were equally distributed in both groups. Subsequently the robustness of this signature was confirmed by blind case-by-case classification of a validation-set composed of the 14 remaining tumors. Results We have identified a signature composed of 224 genes, which discriminates HPV16-induced OPSCC from their HPV-negative counterparts. After the blind classification of the 14 tumours, the viral status was revealed: 13 out of 14 tumors were correctly classified according to tumor etiology, 1/14 was not determined and none were misclassified. Several of the differentially expressed genes were involved in cell-cycle regulation, DNA replication and repair, transcription regulation, immune response and apoptosis. Conclusion Our study contributes to a better understanding of pathogenic mechanisms involved in the development of HPV-positive OPSCCs and in the identification of potential therapeutic targets.